Physician profile
Brody A Flanagin
NPI 1992989065
$33,899.49
in general payments reported to CMS, 2019-2025
14 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,751 · 2020: $4,835 · 2021: $5,211 · 2022: $3,341 · 2023: $4,986 · 2024: $3,902 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,960 · Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,960.00 |
| Food and Beverage | $801.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $24,804.61 | 2019-2025 | Aequalis, Omega, Crossflow |
| Arthrex, INC. | $2,718.00 | 2019-2020 | |
| Wright Medical Technology, INC. | $2,318.58 | 2019 | |
| Pylant Medical | $2,181.43 | 2019-2024 | |
| Medacta USA, INC. | $980.12 | 2020-2021 | |
| Globus Medical, INC. | $407.13 | 2021-2023 | Proximal Humerus Strut |
| Catalyst Orthoscience | $204.47 | 2020-2022 | |
| Depuy Synthes Sales INC. | $83.55 | 2019-2023 | Inhance |
| Smith+Nephew, INC. | $69.36 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $61.23 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $23.66 | 2024 | |
| Zimmer Biomet Holdings, INC. | $21.91 | 2024 | Gps III Platelet Concentration System |
| Horizon Therapeutics Plc | $14.33 | 2019 | |
| Pacira Therapeutics, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brody Flanagin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.